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Abstract
Title: Differences in List Learning Performance on the MoCA wordlist and
Shepherd Verbal Learning Test in Cognitively Normal, MCI, and AD Individuals
Author: Gabrielle Montgomery Gavitt, M.S.
Major Advisor: Anthony LoGalbo, Ph.D.
Objective: The present study examines performance on the MoCA wordlist and
SVLT wordlist and their association with the outcomes of healthy, MCI, and AD in
a memory disorder clinic sample and community sample.
Method: Archival data form 125 Health First Memory Disorder Clinic patients was
utilized. Data from a community sample of geriatric individuals was also utilized.
Participants were included if they were administered both the MoCA and SVLT
and were diagnosed as healthy, MCI, or AD. Additionally, individuals were used
from the community sample of their score was 23 and above on the MoCA.
Patients’ medical and psychosocial information was obtained from their electronic
medical records (EMR).
Results: No significant differences were found on MoCA word list performance
when comparing community healthy controls and healthy controls from the
HFMDC, t(299) = -.87, p = .193, with the difference to have a 95% CI [-.94, .36].
Additionally, there were no significant differences in performance eon the SVLT
when comparing community healthy controls and healthy controls from HFMDC,
t(299) = -.87, p = .193, with the difference to have a 95% CI [-.94, .36]. A
significant difference was found between healthy HFMDC controls and MCI
patients regarding performance on the MoCA wordlist, t(198) = -7.73, p <.001,
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with the difference to have a 95% CI [-2.24, -1.33]. Additionally, a significant
difference was also found between healthy HFMDC controls and MCI patients
performance on the SVLT, t(198) = -7.84, p <.001, with the difference to have a
95% CI [-3.43, -2.05]. A significant difference was found between healthy
HFMDC controls and AD patients regarding their performance on the MoCA
wordlist, t(55.83) = -14.78, p < .001, with the differences to have a 95% CI [-3.23, 2.45]. There was also a significant difference found between healthy HFMDC
controls and AD patients regarding their performance on the SVLT, t(63.58) = 20.25, p < .001, with the differences to have a 95% CI [-6.11, -5.01]. Furthermore,
a significant difference was found between MCI patients and AD patients with their
performance on the MoCA wordlist, t(180.7) = -8.28, p < .001, with the differences
to have a 95% CI [-1.30, -.80]. There was also a significant difference found
between MCI patients and AD patients with their performance on the SVLT,
t(214.12) = -13.69, p < .001, with the difference to have a 95% CI [-3.23, -2.41].
An increase in MoCA delayed recall on the wordlist was associated with an
increase in the odds of higher cognition based on diagnosis, with an odds ratio of
2.92 (95% CI, 2.41 to 3.52), Wald χ2(1) = 123.110, p < .001. Also, an increase in
SVLT delayed recall was associated with an increase in the odds of higher
cognition based on diagnosis, with an odds ratio of 2.27 (95% CI, 2.01 to 2.58),
Wald χ2(1) = 166.054, p < .001
Conclusion: The results of this present study indicate SVLT and MoCA wordlist
performance can indicate an increase in the odds of higher cognition based on
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diagnosis. Additionally, there were significant differences between all groups on
both the SVLT and MoCA, indicating both appear to have adequate diagnostic
capabilities. However, due to the brief nature of the MoCA it is still important to
only use as a screener. The SVLT, though, is likely an adequate and brief measure
regarding verbal memory, and results on this can likely predict cognitive
capabilities regarding verbal memory, thus aiding in providing diagnostic clarity in
healthy individuals, MCI patients, and AD patients.

v

Table of Contents
Chapter 1 Introduction ...……………………………………………..…………….1
Chapter 2 Normal Cognition in Aging ………….…………………..………...…..10
Chapter 3 Mild Cognitive Impairment …………………...……………………….11
Clinical Definition…..……………………………………………………..11
Early History and Overview……………………………………………….12
Epidemiology ……………..………………………………………………13
Risk Factors ………………….……………………………………………13
Chapter 4 Alzheimer’s Disease …………………………………...………………14
Clinical Definition …………………...……………………………………14
Overview …………………………………………...……………………..15
Epidemiology ……………………………………...……………………...16
Risk Factors …..……………………………………………………….…..14
Chapter 5 Use of the MoCA to Assess for MCI ………..……………...…………18
Chapter 6 Factors that Affect Cognition …...……………………………………..20
Chapter 7 Research Objective …………………………….………………………22
Chapter 8 Study Hypotheses ……………………………….……………………..23
Chapter 9 Methods and Procedures ……………………………...………………..24
Data Collection ………………………….……………………….………..24
Measures ………………………………...………………………………...25
Procedures ……...……………………...…………………………….……27
Research Design and Analysis of Data …………………………………....29

vi

Chapter 10 Results …..………………………………………………...….………31
Healthy Community Controls and Healthy HFMDC Controls……………31
Descriptive Statistics…………….………………………………...….…...33
MoCA Wordlist Performance for Healthy HFMDC Controls and MCI
Patients…………………………………………………………...….…….34
SVLT Wordlist Performance for Healthy HFMDC Controls and MCI
Patients ………………………………………………………...….………35
MoCA and SVLT Performance in AD Patients ………………...….……..36
MoCA Performance and Severity of Cognitive Impairment……….……..41
SVLT Performance and Severity of Cognitive Impairment………..……..41
MoCA and SVLT Performance in Amnestic MCI and Non-amnestic
MCI …………………………………………………..………...….……...41
MoCA and SVLT Performance in Within Normal Limits and
Non-amnestic MCI ………………..…………………………...….…..…. 44
MoCA and SVLT Wordlist Performance for Combined Healthy Controls
and MCI Patients ……………………………………………...….…….....46
MoCA and SVLT Performance in Combined Healthy Controls and
AD Patients …………………….……………………………...….…..…. 48
MoCA and SVLT Performance in Combined Within Normal Limits
and Non-amnestic MCI………………………………………………….…49
Chapter 11 Discussion ……………………...………………….…...…….……….50
Chapter 12 Limitations ………………………………………………...…....…….59

vii

Chapter 13 Conclusions ………………………...…….……………….....….……61

viii

List of Figures
Figure 1- Community Healthy Controls and Healthy HFMDC MoCA......32
Figure 2- Community Healthy Controls and Healthy HFMDC SVLT......33
Figure 3- Diagnosis....................................................................................34
Figure 4- Gender........................................................................................34
Figure 5- Ethnicity.....................................................................................34
Figure 6- Race...........................................................................................34
Figure 7- Healthy HFMDC Controls and MCI Patients MoCA................35
Figure 8- Healthy HFMDC Controls and MCI Patients SVLT.................36
Figure 9- Healthy HFMDC Controls and AD Patients MoCA..................37
Figure 10- Healthy HFMDC Controls and AD Patients SVLT.................38
Figure 11- MCI Patients and AD Patients MoCA….................................39
Figure 12- MCI Patients and AD Patients SVLT......................................40
Figure 13- aMCI Patients and Non-Amnestic MCI Patients MoCA….....42
Figure 14- aMCI Patients and Non-Amnestic MCI Patients SVLT..........43
Figure 15- MoCA Performance with WNL and Non-amnestic
MCI………………………………………………………..….....45

ix

Figure 16- SVLT Performance with WNL and Non-amnestic
MCI………………………………………………………..….....46

x

Acknowledgement
I would like to thank my advisor, Dr. LoGalbo, for his help and guidance on this
project. I would also like to extend my appreciation to my committee members, Dr.
Tyc and Dr. Dorfeld, for their support on this project as well. I’d also like to thank
the Health First Memory Disorder Clinic for allowing Florida Institute of
Technology students for providing an enriching educational environment and the
chance to engage in research opportunities. I’d also like to thank the patients at the
memory clinics and the participants in the geriatric normative data who consented
to this research project. I would also like to thank my mother for her selflessness as
a single mother that led to be going to graduate school and following her footsteps
of being a member of the United States Air Force. Without her constant
encouragement I would not be where I am today.

xi

Gavitt

1

Chapter 1 Proposal Introduction
The human nervous system is comprised of two mains systems, the central
nervous system, which includes the brain and spinal cord, and peripheral nervous
system, which contains nerves beyond the brain and spinal cord (Hurtley &
Alderton, 2020). Neurodegeneration is a term used to describe when an individual’s
nervous system undergoes progressive atrophy and a loss of function of the
neurons. Because this can occur in the brain, spinal cord, or peripheral nerves,
neurodegenerative processes can cause a multitude of symptoms such as physical
weakness or immobility, apathy, anxiety, loss of inhibition, mood changes, and
cognitive changes such as memory loss (Hurtley & Alderton, 2020).
Neurodegenerative diseases can occur for several reasons such as mitochondrial
dysfunction, oxidative stress, and/or environmental factors (Sheikh et al., 2013).
Aging often plays a dominant role in neurodegenerative processes. Although aging
can affect every organ in the human body, the impact of aging on the brain has
some of the most distressing symptoms due to our reliance on having intact
cognition. Neurodegenerative diseases have become an increasingly prevalent
threat to human health due to the fact that humans are living longer (Gitler et al.,
2017). As noted above, neurodegenerative diseases can affect vital functions such
as cognition and memory as well as the ability to move, speak, and even breathe.
Some examples of prominent neurodegenerative diseases are multiple sclerosis,
Huntington’s disease, amyotrophic lateral sclerosis, frontotemporal dementia,
Parkinson’s disease and Alzheimer’s disease. Early detection of these diseases is
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key to initiating therapies promptly, so they have the most beneficial effect (Gitler
et al., 2017)
There are several strategies which can be useful in detecting
neurodegenerative diseases. Initially individuals begin to experience a clinical
presentation of symptoms, which may be more thoroughly examined during a
medical evaluation. Neuroimaging can also provide evidence regarding the areas of
the brain which are negatively affected, and imaging strategies such as magnetic
resonance imaging (MRI), single photon emission computed tomography (SPECT)
positron emission tomography (PET), and amyloid imaging are all helpful tools in
identifying areas of the central nervous system where atrophy or dysfunction is
occurring (Shimizu et al., 2018). Additionally, identification of potential
biomarkers is also helpful in identifying neurodegenerative processes, and this can
be achieved with a MRI, dopamine transporter (DAT) imaging, and
metaiodobenzyl-guanidine (MIBG) myocardial scintigraphy (Schimizu et al.,
2018). Finally, identification of biochemical changes that led to misfolding and
accumulation of particular proteins is vastly helpful in identifying the
neurobiological processes of neurodegeneration (Telling, 2019). Although these
techniques allow providers to identify the structural and biological changes
occurring in the brain, other strategies are important in identifying the cognitive
changes and behavioral impairments demonstrated by the individual (Rascovsky,
2016).
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Specifically, neuropsychological testing can be integral in identifying the
extent and severity of an individual’s cognitive and behavioral dysfunction within
the central nervous system, whether that be due to neurodegenerative processes or
an injury to the brain (Rascovsky, 2016). Neuropsychological tests are traditionally
paper-and-pencil tests where an individual will answer a series of questions to
measure cognitive domains (Kessels, 2018). With advances in technology, some of
these measures can now be administered electronically (Kessels, 2018).
Neuropsychological tests directly communicate individuals’ cognitive strengths and
weaknesses, providing information regarding the functioning of the individual’s
brain being tested (Rascovsky, 2016). Neuropsychological testing can allow for
detection and understanding of discrete brain functions to aid in the enhancement
of diagnostic and treatment outcomes (Casaletto & Heaton, 2017). Overall, the
main goals of neuropsychological assessment are to identify the degree of
neurocognitive dysfunction and aid in differential diagnosis, identify cognitive
strengths and weakness, and aid in providing recommendations on adapting to life
and treatment planning (Casaletto & Heaton, 2017).
To achieve the goals of neuropsychological testing, a variety of cognitive
domains are measured to determine whether potential strengths or weaknesses exist
within those domains. Typical domains measured include sensation, perception,
motor skills and construction, attention and concentration, executive functioning,
processing speed, language/verbal skills, and memory (Harvey, 2019). Within these
domains, there are several subdomains to provide an in-depth analysis of
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neurocognitive functioning. Of note, these domains approximate those outlined in
the diagnostic criteria of neurocognitive disorders according to the Diagnostic and
Statistical Manual of Mental Disorders, Fifth Addition (DSM-5) (American
Psychiatric Association, 2013).
Neurocognitive disorders (NCD) within the DSM-5 refer to disorders with
an identifiable underlying brain pathology and a potential etiology which can be
determined (American Psychiatric Association, 2013). There are three categories of
neurodegenerative disorders including delirium, mild NCD, and major NCD, and
minor NCD and major NCD can be further diagnostically clarified by specifying an
etiological subtype (if known or suspected). NCDs are measured and determined
based on several cognitive domains including complex attention, executive
functioning, learning and memory, language, perceptual-motor abilities, and social
cognition. These are evaluated with assessments, presenting symptoms, and
impairments in everyday activities (American Psychiatric Association, 2013).
There is little research regarding the neuropsychology of delirium as
delirium is based on a disturbance in attention and awareness that develops over a
short period of time representing a change from the individual’s baseline, and due
to the transient nature of this NCD, diagnosis with neuropsychological assessment
is not as stressed (Tieges et al., 2017). However, neuropsychological testing is quite
important regarding the diagnosis of mild or major NCD (Lucza et al., 2015).
According to the Diagnostic and Statistical Manual of Mental Disorders, 5th
edition (2013), a mild NCD is diagnosed when there is evidence of a modest
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decline in previous level of performance in one or more cognitive domains, no
change in carrying out instrumental activities of daily living even if compensatory
strategies are used, exclusion of delirium, and exclusion of other mental disorders.
The diagnosis of a major NCD occurs when there is a significant cognitive decline
from a previous level of performance in one or more cognitive domains as well as
interference with independence in everyday activities. Additionally, these deficits
must not occur in the context of delirium and the symptoms cannot be better
explained by another mental disorder (American Psychiatric Association, 2013).
For both mild NCD and major NCD, the specifiers Alzheimer’s disease,
frontotemporal lobar degeneration, Lewy body disease, vascular disease, traumatic
brain injury, substance/medication use, HIV infection, prior disease, Parkinson’s
disease, Huntington’s disease, another medical condition, multiple etiologies, and
unspecified can be utilized to further clarify the minor or major NCD (American
Psychiatric Association, 2013).
The DSM-5 diagnoses of mild or major neurocognitive disorder allows for
clarifying diagnoses regarding neurodegenerative processes. Although the DSM-5
includes specifiers such as Alzheimer’s disease, a commonly diagnosed condition
referred to as mild cognitive impairment (MCI) is not specifically mentioned in the
DSM-5. This apparently occurred due to NCD being a diagnosis relating to
cognitive impairment at all ages, while MCI is more associated with geriatric
disorders (Ganguli, 2013). Over the past two decades, mild cognitive impairment
(MCI) has been heavily researched and utilized as an interim diagnostic phase
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between normal aging and dementia, with dementia referring to acquired cognitive
impairment that interferes with social and occupational functioning (Peterson,
1999). The diagnostic criteria for MCI are used from the Mayo Criteria, which
were created at the Key International Symposium in 2003 (Peterson, 2016).
Amnestic MCI refers to impairments regarding the memory domain and is the most
associated with probable dementia of the Alzheimer’s type (AD) (Schmidtke &
Hermeneit, 2008).
Although one measure cannot definitively predict whether someone is
experiencing MCI, dementia, or a neurodegenerative process from MCI to
dementia, several neuropsychological assessments are crucial for determining these
diagnoses. Measures regarding verbal learning and recall are key in determining
amnestic MCI, AD, and the potential progression of MCI to AD (Galluci et al.,
2017). Specifically, story memory and list learning tasks are quite sensitive to the
neurodegenerative effects of MCI and AD (Tremont et al., 2009). These
assessments allow for details regarding the individuals functioning of their episodic
memory, which refers to the individual’s ability to learn and recall personal
experiences (Gavett et al., 2016). A decline in episodic memory is usually due to
medial temporal lobe pathology, and early detection of this decline is an important
indicator of the neurodegenerative processes of AD. This early indication can be
achieved with cognitive tests involving story memory and list learning activities
before the neuropathologies are detectable utilizing neuroimaging (Gavett et al.,
2016).
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A study researching 55 amnestic MCI patients found that the Rey Auditory
Verbal Learning Test (RAVLT), Delayed Recall (p = .031) and Semantic Verbal
Fluency tests (p=.031), verbal memory and language tests, respectively, were the
most helpful tools in predicting the progression of amnestic MCI to dementia.
Individuals with lower scores on these tests were shown to be at risk of developing
dementia (Galluci et al., 2017). The RAVLT is comprised of 15 concrete nouns that
are read to the participant in a list for 5 trials (Magalhaes & Hamden, 2010). After
each trial, the participant is asked to repeat back all the words they remember. After
the first 5 trials, a second list is read to the participant with 15 different concrete
nouns, and the participant is again asked to repeat back what they remember from
the second list. Then, the participants are asked to state words they remember from
the first list. After a 20-minute delay, participants are asked to recall what words
they remember from the first list. The final task on the RAVLT is the participant
being orally presented 50 nouns from both lists, and the participant is required to
identify words from the first list (Magalhaes & Hamden, 2010).
Additionally, research involving another verbal list learning test called the
California Verbal Learning Test (CVLT) has provided further evidence regarding
the importance of list learning tasks in the detection of early Alzheimer’s disease in
MCI patients (Pozueta et al., 2011). In this study of 109 MCI patients,
neuropsychological evaluations were conducted at baseline and at 6-month
intervals for 2 years. It was found that 54 of these individuals progressed from MCI
to dementia, while 55 maintained the diagnosis of MCI. A strong predictor that
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determined the progression of MCI to dementia was episodic memory impairment,
and this was determined based on performance on the CVLT with short and long
delay recall and both free and cued recall. Individuals who retained the diagnosis of
MCI performed better overall on the CVLT. This study concluded that it is possible
to determine a pre-AD amnestic MCI at baseline using the CVLT (Pozueta et al.,
2011).
The Montreal Cognitive Assessment (MoCA) is a screening measure
utilized to determine if an individual is demonstrating cognitive difficulties
(Nasreddine et al., 2005). The MoCA includes a 5-word list to measure verbal
learning and delayed recall. These 5 words are read twice consecutively to see how
many the examinee remembers, and then the examinee is asked to recall these
words again after approximately 5 minutes. Thus, up to 5 of the total points on the
MoCA are derived from one’s ability to remember these 5 words. If most of the
points lost on the MoCA are derived from the word list, then the examinee may be
assumed to have amnestic MCI (Li et al., 2018).
Word list-learning tasks are fairly common and useful measures of verbal
memory and retention and can help in differentiating impairments based on
memory difficulties (Lie et al., 2018). However, the 5-item word list on the MoCA
is relatively short compared to other word list-learning tests, and therefore it may
not be capable of detecting early or milder memory impairments such as those
observed in individuals with MCI. A longer word list could potentially be useful in
identifying those with milder impairments (Lie et al., 2018). Early detection of mild
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cognitive changes in the elderly is imperative, as interventions with those who have
MCI can improve brain functioning. For example, cognitive or memory training
has shown to enhance activity in the frontal, temporal, and parietal areas of the
brain (Chen & Wang, 2013). Additionally, there are memory medications such as
cholinesterase inhibitors that help to manage symptoms as well as potentially slow
progression of neurocognitive decline (Chen & Wang, 2013).
The Shepherd Verbal Learning Test (SVLT) is a word list-learning task
developed for use with older adults with cognitive impairment at the Health First
Memory Disorder Clinic (Norheim, N., Kissinger-Knox, A., Cheatham, M.,
Mulligan, K., & Webbe, F., 2018). It has characteristics that are similar to existing
verbal memory tasks that involve word lists, with some differences as well. For
example, there are ten words in total on the SVLT, which is more than the number
of words in the MoCA (which has 5), but fewer than the number of words on the
most recent version of the CVLT (the CVLT-3, which has 16). Additionally, the
SVLT words are relatively grammatically simple being that they are only one
syllable each. This list is repeated over 5 trials and the examinee is asked to recall
as many words as possible after each trial, which provides information regarding
the individual’s ability to learn repeated verbally presented information. After the 5
trials are completed, there is a 5-minute delay after which the examinee is prompted
to recall as many words from the list as possible, as a way to measure delayed
verbal recall. Finally, 10 minutes after the delayed recall, the individual is given a
sheet of paper with two columns of words, each column containing ten words. Ten
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of the words were on the original list, while ten of the words were not on the list,
and the individual is asked to circle the words that were on the list. The SVLT is
relatively simple to administer in a brief amount of time and the results are easy to
interpret. Although it is shorter in comparison to other word lists, it appears to be a
valid measure of verbal memory. The current study aims to determine whether the
SVLT’s longer word list is more accurate than the MoCA’s shorter word list in
predicting memory disorders, such as amnestic MCI.
Chapter 2 Normal Cognition in Aging
As individuals age, it is normal for subtle neurocognitive changes to occur.
Even with a neuropsychological assessment, it can be quite difficult to determine
what constitutes normal cognitive changes from pathological cognitive
impairments. Additionally, several other factors can influence cognition, including
educational background, psychological distress, vascular risk factors, and other
health conditions (Harada et al., 2013). However, age-related cognitive changes are
often considered normal if the person is still capable of carrying out activities of
daily living (Harada et al., 2013). In healthy older adults, it is more likely that they
will demonstrate mild relative difficulties in working memory, episodic memory,
and tasks of attention in comparison to younger adults. Although there is some
degree of measurable decline within these domains, older adults perform better on
assessments in which wisdom and general knowledge is tested (Dumas, 2015).
Because of these expected changes in cognition with normal aging,
obtaining accurate normative data for individuals experiencing normal cognitive
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aging is extremely important. This normative data allows for accurate diagnosis
and treatment of neurodegenerative diseases when assessing older adults because
their test results can be compared to others who are their own age. Unfortunately,
the literature is limited regarding normative data for healthy aging populations and
performing normal aging related assessments. Humans are living longer, meaning
there needs to be new norms created for these older age groups to aid in diagnostic
clarity. The “oldest-old,” a label created for individuals 85 and older, is a
population with substantially limited normative data regarding neuropsychological
assessments. However, Miller et al. (2015) obtained normative ranges for several
assessments, as the oldest-old is a growing population. In this study it was found
that overall, there are measurable cognitive declines as individuals age, which is
congruent with the use of age-appropriate normative data for the oldest-old people
(Miller et al., 2015).
Chapter 3 Mild Cognitive Impairment
Clinical Definition. The specific diagnostic criteria and definition of MCI
was set forth during the Key International Symposium in 2003 (Petersen, 2016).
One of the goals of this symposium was to create distinctions between the different
types of MCI, as not all MCI subtypes develop into AD. The initial diagnostic
feature that the Key International Symposium identified was that the individual was
experiencing a cognitive shortcoming. If these cognitive difficulties were not
related to normal aging, but also not related to dementia, the cognitive decline was
steady, and the individual exhibited relatively normal functional activities, then the
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individual could be diagnosed with MCI. Cognitive screening measures are often
used to identify MCI, such as the Mini-Mental State Exam (MMSE) and Montreal
Cognitive Assessment (MoCA). However, more comprehensive
neuropsychological assessments are beneficial in differentiating MCI subtypes.
Specifically, the distinction between having memory impairment, or amnestic MCI,
and not having memory impairment, or non-amnestic MCI, has been identified.
Additionally, having impairments only within a single cognitive domain, versus
having impairments in multiple domains, has been conceptualized as another
diagnostic clarification for MCI (Petersen, 2016). It is also of note that MCI can be
considered to be a subset of mild NCD, as they can both manifest as an
intermediate stage between normal aging and dementia (Geda & Nedelska, 2013).
Early History and Overview. Although a diagnosis of MCI is not
considered to be as severe as dementia, it has been known for decades that early
detection of cognitive deficits is possible and beneficial for purposes of treatment
and future planning. The first indications of an MCI-like diagnosis occurred in
1962, when the term “benign senescent forgetfulness” was utilized (Kral, 1962).
Dr. V.A. Kral observed that there was a decline in memory functioning as
individuals aged. By 1980, the Diagnostic and Statistical Manual of Mental
Disorders, 3rd edition (DSM-III) identified a syndrome considered to be a primary
degenerative dementia that would likely develop into AD (American Psychiatric
Association, 1980). The criteria for this diagnosis reiterated that there needs to be
evidence of a progressive deterioration in multiple domains of an individual’s life.
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Although the criteria detailed for primary degenerative dementia is not as
encompassing as the current criteria for MCI, it is considered to be one of the
preceding diagnoses to MCI.
Epidemiology. The prevalence of MCI has been estimated to range from
12% to 18% in individuals over the age of 60 years, while in individuals over the
age of 70, the prevalence of MCI is 16% (Petersen, 2016). It has been found that
MCI amnestic single domain has a lower prevalence of only 2% to 4%, while other
MCI subtypes make up 18% to 21% of MCI patients (Lopez, 2013). It has been
found that 10-15% of patients diagnosed with MCI will progress to AD annually
(Varatharajah et al., 2019). Being aware of this distinction regarding types of MCI
is quite important, as it can predict the area of cognitive decline and create targeted
prevention (Peterson et al., 2014). For example, in a study looking at 1188
individuals diagnosed with MCI, 32% progressed to dementia in an average of 2
years (Glynn et al., 2020). Of the 1188 individuals, 55% were diagnosed with
amnestic MCI, and the remaining 45% were diagnosed with non-amnestic MCI
(Glynn et al., 2020). It was found amnestic MCI was a significant predictor of the
individual’s progression in their cognitive deficits when compared to non-amnestic
MCI, as individuals were twice as likely to progress to dementia if they were
diagnosed with amnestic MCI. (Glynn et al., 2020).
Risk Factors. The risk factors for MCI are fairly similar to that of the risk
factors of AD (Chen et al., 2018). For example, increasing age is a risk factor for
developing MCI similar to that of AD. Additionally, vascular risk factors such as
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hypertension, dyslipidemia, anemia, heart disease, and stroke are also related to an
increased risk in developing MCI, and these are also risk factors for AD. Other risk
factors include liver disease, renal disease, and gastrointestinal disease. Depression
is also a risk factor for developing MCI. The use of more than five medications was
also found to be a risk factor (Chen et al., 2018). In a study examining 294 elderly
patients, it was found that 54% of patients who were taking 10 or more medications
were demonstrating impaired cognition (Jyrkkä et al, 2011). Additionally, 33% of
patients taking 6-9 medications, and 22% taking five or fewer medications,
exhibited impaired cognition (Jyrkkä et al, 2011).
Chapter 4 Alzheimer’s Disease
Clinical Definition. A diagnosis of dementia requires cognitive or behavioral
symptoms to be severe enough to interfere with an individual’s ability to function
at work or other domains of life (McKhann et al., 2011). Additionally, a decline in
functioning compared to previous levels must be established. The degree of
cognitive impairment must be diagnosed from knowledge of a thorough clinical
history of the individual and a comprehensive cognitive assessment. Cognitive or
behavioral impairment must be observed in at least two of the following domains:
ability to acquire and remember new information, reasoning and handling of
complex tasks, visuospatial abilities, language functions, and changes in
personality or behavior (McKhann et al., 2011). To more specifically diagnose
probable AD dementia, there needs to be presence of an insidious onset, a clear
history of cognition worsening by either report or observation, and an amnestic
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presentation with language, visuospatial, or executive difficulties (McKhann et al.,
2011).
Overview. Alzheimer’s disease is the most common cause of dementia and is
attributed to 80% of all dementia diagnoses (Weller & Budson, 2018). This disease
is named after Dr. Alois Alzheimer, who in 1907 treated a woman who he noticed
had died from “unusual mental illness” and had changes in her brain tissue. He
discovered she had clumps and fibers in her brain, which were subsequently
identified as amyloid plaques and neurofibrillary tangles after further research. He
also observed her to have memory loss as well as language problems and odd
behavior (Bondi et al., 2018).
Research involving AD was sporadic after the initial identification of this
disease. One of the main reasons AD was not researched heavily was due to
neuropsychological studies of dementia and AD only focusing on individuals
exhibiting symptoms before the age of 65, which is rarer. However, in the mid1970s, epidemiological data revealed that AD was the fourth leading cause of death
in the elderly. This led to greater attention to AD as well as funding research into
this disease and refining diagnostic clarity (Bondi et al., 2018).
By the 1980s, research was being conducted on mildly demented patients using
methods of cognitive psychology to explore the nature of potential
neuropsychological deficits in AD. These studies helped to outline the common
neuropsychological presentation of AD, which included impairments in episodic
memory and semantic encoding. Additionally, it was observed that although there
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will likely be executive functioning impairments and deficits in attention for those
with AD, these deficits played a less prominent role. Lastly, some patients did
display visuospatial deficits; however, these deficits were less salient than the other
cognitive deficits observed.
Several genetic risks for AD were identified during the 1990s and early 2000s,
which led to increased diagnostic clarity (Bondi et al., 2018). There has also been
advances in neuroimaging regarding the diagnosis of AD. For example, it has been
found that in individuals with AD, there is atrophy in structures within the medial
temporal lobe. As the disease progresses, there is likely to be atrophy with
structures in the medial temporal lobe such as the hippocampus, amygdala,
entorhinal cortex, and parahippocampal cortex (Ledig et al, 2018).
Epidemiology. As noted above, Alzheimer’s disease cannot be definitively
diagnosed until after death. However, if there is no other cause for dementia found,
and the symptomatology matches typical AD symptoms, an individual may be
diagnosed with possible or probable Alzheimer’s dementia while living. This
diagnosis may be derived from a detailed assessment performed by a geriatrician,
geriatric psychiatrist, neurologist, neuropsychologist, or a combination of these
professionals (U.S. Department of Health and Human Services, 2017). By the
middle of the 21st century, it is predicted that 13.8 million American individuals
will suffer from Alzheimer’s dementia, which is a large increase compared to the
5.8 million American individuals who suffer from AD currently. In 2018, 122,019
people died from Alzheimer’s disease, making it the 6th leading cause of death in
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the United States. Currently, in 2021, 6.2 million Americans over the age of 65 are
living with AD, and 72% of these individuals are 75 or older. Additionally, twothirds of these individuals with AD are women, and black Americans are twice as
likely to develop AD in comparison to white Americans. Hispanic Americans are
1.5 times as likely to develop AD when compared to white Americans
(Alzheimer’s Association, 2020).
Risk Factors. The three most prominent risk factors of Alzheimer’s disease are
age, genetics, and family history (Alzheimer’s Association, 2020). Other risk
factors for AD include vascular diseases, type 2 diabetes, traumatic brain injury,
epilepsy, and depression (Edwards et al., 2019). The risk of AD increases as people
age, with about 3% of diagnoses of Alzheimer’s disease occurring between the ages
of 65 to 74. Once between the ages of 75 to 84, 17% of people have Alzheimer’s
disease, and once over the age of 85, 32% of people have Alzheimer’s disease
(Alzheimer’s Association, 2020). Additionally, genetics plays a role in the risk of
developing Alzheimer’s disease. A gene found to be linked to AD is the
apolipoprotein-e4 (APOE-e4) gene allele. The APOE gene controls the protein that
takes cholesterol to the bloodstream, and the e4 allele increases risk of developing
AD, as 40-65% of individuals with AD have the e4 allele (Van Cauwenberghe et
al., 2016). The e2 allele actually has a protective effect regarding the development
of AD (Van Cauwenberghe et al., 2016). Finally, family history plays an important
role in the development and diagnosis of AD. It has been found that those who
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have had a parent with AD increases their risk by 30% (Alzheimer’s Association
2020).
Chapter 5 Use of the MoCA to Assess for MCI
The MoCA was created as a screening tool specifically for detecting MCI
(Nasreddine et al., 2005). The MoCA is scored out of a possible total of 30 points,
and the cut point of 25/26 has a sensitivity of 80 to 100% and specificity of 50 to
76% for detecting MCI (Langa & Levine, 2015). The creators claim the MoCA is
capable of screening for a myriad of disorders such as Alzheimer’s disease,
Parkinson’s disease, Lewy body dementia, stroke, fronto-temporal dementia, brain
metastasis, brain tumors, amyotrophic lateral sclerosis, multiple sclerosis, and head
trauma (mocatest.org). Additionally, diagnoses that would not be considered to
have as severe of a cognitive impairment as the previous listed ailments are also
claimed by the creators of the MoCA to be detected by this screener, including
depression, schizophrenia, heart failure, substance use, and HIV (mocatest.org).
Regarding Parkinson’s disease, the MoCA demonstrated adequate psychometric
properties as a screener for MCI or dementia in Hoops et al.’s 2009 study looking
at the MoCA’s validity for diagnosing MCI or dementia in Parkinson disease;
however, additional assessment was required due to lower than ideal specificity
when looking at the MoCA’s specific cut point. Furthermore, although the MoCA
may be a useful tool in detecting cognitive difficulties or potential dementia, it also
detects a high proportion of false positives. In a systematic review looking at the
MoCA for the diagnosis of AD and other dementia, the number of individuals that
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were incorrectly diagnosed with dementia was upwards of 40% due to using the cut
score of less than 26 (Davis et al., 2015). Although the MoCA should not
necessarily be used for diagnostic purposes in isolation, it appears to be an
adequate tool for utilizing as a screener for cognitive difficulties, such that scoring
below the normal range would warrant further diagnostic investigation
(Dautzenberg et al., 2020).
The MoCA is a screener capable of detecting some degree of cognitive
changes; however, given its brevity, it often does not provide enough data to allow
for specific diagnostic clarity. For example, although the MoCA is more sensitive
in detecting MCI compared to a clinical interview or ad hoc questions, it may not
be comprehensive enough to identify more subtle presentations of MCI (Knopman
& Peterson, 2015). It is important to identify cases that may be missed by the
MoCA so that action can be taken toward intervention. Additionally, taking further
action can help to gauge the likelihood of progression. Therefore, using a screening
instrument such as the MoCA by itself could result in some cases of MCI being
undetected, also known as “false negatives.” When an individual is diagnosed with
MCI, it carries important prognostic implications as individuals diagnosed with
MCI are at a higher risk of progressively worsening to Alzheimer’s disease or other
types of dementias (Knopman & Peterson, 2015). Therefore, a high level of
accuracy in detecting cases of MCI is critical. Furthermore, the ability to accurately
classify MCI subtypes has become increasingly relevant as well. In particular, if
memory loss is a predominant feature when diagnosing MCI, then the MCI
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diagnosis is further specified as “amnestic” in nature. This sub-classification is an
important factor in diagnosing MCI, as individuals with amnestic MCI have an
even a higher risk of converting to Alzheimer’s disease specifically, while nonamnestic MCI has a higher risk of converting to non-Alzheimer’s dementia (Csukly
et al., 2016).
The MoCA can also be utilized to determine if individuals are functioning
at a “healthy” cognitive level (Bruijen et al., 2020). In a study of 210 individuals
aged 18 to 70 who were administered the three different versions of the MoCA
found that the MoCA is a reliable cognitive measure. Additionally, all three MoCA
versions were relatively equivalent. However, it was also found that age, education,
and intelligence are predictors of MoCA performance in health individuals (Bruijen
et al., 2020).
Chapter 6 Factors that Affect Cognition
Age
Throughout human’s lives, there are changes in cognition (Murman, 2015).
Whether that be attention, memory, executive functioning, language, or visual
spatial abilities, changes in cognition occur. A strong factor that effects cognition is
aging. Regarding attention, the most noticeable change that occurs when people age
is with complex attentional tasks such as selective or divided attention.
Additionally, older adults’ memory changes as there are a decline in new learning
abilities as well as retrieval of newly learned material. Aging individuals have
stable immediate memory, episodic memory, and procedural memories. However,
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new learning that can be measured by delayed free recall declines with age. This
can be measured with a list learning task. Working memory and prospective
memory also declines with age. Another area of cognition that declines with age is
executive functioning. This includes tasks related to decision making, problem
solving, planning, sequencing, and multitasking. Speech and language stay
relatively intact through aging, Visual-spatial skills also decline with age (Murman,
2015).
Sex
Sex also plays a role in cognition related to aging (Reas et al., 2018). In a study
examining 2,225 community-dwelling participants (59% women) were provided
neuropsychological testing every four years over a maximum of a 27-year follow
up. It was found that cognitive decline occurred between the ages of 65 to 80, with
more rapid acceleration occurring after the age of 80. It was found that the rate of
decline was similar between sexes; however, males declined more rapidly on a
global function test. Women, though, showed a more rapid decline than men on a
test of executive functioning (Reas et al., 2018).
Education
Education can also play an important role regarding aging. In a study looking at
659 cognitively normal community dwelling individuals, it was found that the
highly educated elderly had better functioning in a variety of areas (Chen et al.,
2019). For example, these individuals performed better in several cognitive
domains. There were also slower age-related reductions of executive functioning
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(Chen et al., 2019). Additionally, in another study of 938 individuals that were 75
and older, six cognitive assessments were provided with a final follow up 15 years
after the baseline assessment (Then et al., 2016). It was found that more years of
education had a protective effect on dementia risk (Then et al., 2016).
Health Difficulties
There are a variety of risk factors that can affect dementia and its progression
(Livingston et al., 2020). Several risk factors that have been identified are hearing
impairment, obesity, depression, diabetes, and traumatic brain injury. Additionally,
smoking, depression, and physical activity also have been shown to effect dementia
(Livingston et al., 2020).
Chapter 7 Research Objectives
This research aims to determine whether the 5-word list assessing memory on the
MoCA is sensitive enough to determine whether someone is ultimately diagnosed
with amnestic MCI. This will be accomplished through an analysis of cognitively
intact individuals, patients diagnosed with MCI, and patients diagnosed with AD
who have been administered both the MoCA and the SVLT word list. The primary
aim of this research is to identify if the SVLT is better at detecting MCI than the
word list on the MoCA. Specifically, it is hypothesized that the longer 10-word
SVLT list will be more sensitive in detecting amenstic MCI compared to the
shorter 5-word list from the MoCA. Performances on the MoCA and SVLT
including comparisons to individuals with AD will also be explored to determine
their relative usefulness in evaluating increasing levels of cognitive impairment.
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Results of this study will be important for aiding in the early detection of amnestic
MCI, which will allow for improved diagnostic implications to mitigate the
potential progression into AD (Reisberg et al., 2008).
Chapter 8 Study Hypotheses
Hypothesis 1.
Healthy controls and individuals diagnosed with MCI will have similar
delayed recall total scores on the MoCA, suggesting that the MoCA word list does
not consistently or comprehensively differentiate MCI from normal cognition.
Hypothesis 2.
Healthy controls will have better delayed recall total scores on the SVLT
than individuals diagnosed with MCI, suggesting the SVLT is better able to
differentiate MCI from normal cognition.
Hypothesis 3.
Individuals diagnosed with AD will have lower delayed recall total scores
on both the MoCA and the SVLT compared to healthy controls and individuals
diagnosed with MCI suggesting that both tests are useful in detecting dementia.
Hypothesis 4.
Lower delayed recall total scores on both the MoCA and the SVLT are
more likely to be associated with more impaired levels of overall cognition based
on diagnosis (Healthy, MCI, AD).
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Hypothesis 5.
Individuals diagnosed with amnestic MCI will have lower delayed recall
total scores on the SVLT compared to individuals diagnosed with non-amnestic
MCI, but not the MoCA, suggesting that the SVLT is better able to differentiate
amnestic MCI and non-amnestic MCI.
Hypothesis 6.
Individuals who performed within normal limits and were diagnosed with
non-amnestic MCI will have similar scores on the MoCA wordlist, but not the
SVLT, suggesting the SVLT is better able to differentiate non-amnestic MCI from
within normal limits.
Chapter 9 Methods and Procedures
Data Collection
This study utilized test data collected from community-dwelling healthy
controls who participated in a research study which obtained normative data for
several neuropsychological tests. These individuals were eligible for participation
in this research if they were 65 years and older and were not demonstrating
cognitive impairments. Specifically, individuals’ data was included if they scored
23 or above on the MoCA. Data was also utilized from the HFMDC database.
These individuals were administered a MoCA and a brief neuropsychological
evaluation. Participants were selected if they performed within normal limits or
were diagnosed with MCI or AD.
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Measures
Community-dwelling healthy controls were administered several
neuropsychological measures to be included in normative data collection. The
following tests were administered: MoCA, Test of Memory Malingering (TOMM),
Brief Visual Memory Test-Revised (BVMT-R), Boston Naming Test Short Form,
Trail Making Test A & B, and SVLT. The TOMM is a measure of assessment
validity. The BVMT-R is a measure of visual memory, while the Boston Naming
Test Short Form is a measure of language. Finally, the Trail Making Test A & B
measures attention, processing speed, and executive functioning.
Patients who performed within normal limits and diagnosed with MCI and
AD at the HFMDC were administered a brief neuropsychological evaluation that
measured the following cognitive domains: learning and memory, language,
attention and processing speed, executive functioning, visuospatial skills, and basic
functional living skills. The following tests were administered: (a) SVLT, (b)
BVMT-R, (c) Controlled Oral Word Association Test (COWAT), (d) Boston
Naming Test Short Form, (e) Western Aphasia Battery (WAB) Comprehension and
Repetition, (f) Boston Diagnostic Aphasia Examination (BDAE) Cookie Theft
Picture, (g) Trail Making Test A & B, (h) Stroop Color and Word - Golden
version, (i) Wechsler Adult Intelligence Scale-Fourth Edition (WAIS-IV) Digit
Span subtest, (j) Modified Wisconsin Card Sorting Test (M-WCST), (k) Clock
Drawing Test, (l) Geriatric Depression Scale (GDS), (m) Geriatric Anxiety
Inventory (GAI), and the (n) Texas Functional Living Scale (TFLS). The COWAT,
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WAB, and BDAE Cookie Theft Picture are all measures of language. The Stroop
Color and Word – Gold version and WAIS-IV digit span subtest is both measures
of attention. Meanwhile, the M-WCST is a measure of executive functioning, and
the Clock Drawing Test is a measure of visual-spatial abilities. The GDS and GAI
are both mood measures, and finally, the TFLS is a measure of adaptive
functioning.
Montreal Cognitive Assessment (MoCA)
The MoCA (Nasreddine et al., 2005) is a standardized memory screener
used to assess global cognitive functioning. It looks at several domains including
visuospatial, executive functioning, language, attention, memory, orientation, and
abstract reasoning. This measure can detect potential cognitive impairment in
individuals that are aging. The assessment is scored out of a total of 30 points, and
it is interpreted as the higher the score, the more cognitively intact the person is.
Education can also be corrected for individuals who have less than 13 years of
formal education by adding 1 point (Nasreddine et al., 2005).
Shepherd Verbal Learning Test (SVLT)
The Shepherd Verbal Learning Test (SVLT) is a word list-learning task
developed for use with older adults with cognitive impairment at the Health First
Memory Disorder Clinic (Norheim, N., Kissinger-Knox, A., Cheatham, M.,
Mulligan, K., & Webbe, F., 2018). Additionally, the SVLT words are relatively
grammatically simple being that they are only one syllable each. This list is
repeated over 5 trials and the examinee is asked to recall as many words as possible
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after each trial, which provides information regarding the individual’s ability to
learn repeated verbally presented information. After the 5 trials are completed,
there is a 5-minute delay after which the examinee is prompted to recall as many
words from the list as possible, as a way to measure delayed verbal recall. Finally,
10 minutes after the delayed recall, the individual is given a sheet of paper with two
columns of words, each column containing ten words. Ten of the words were on
the original list, while ten of the words were not on the list, and the individual is
asked to circle the words that were on the list.
Procedures
Normative test data from community-dwelling healthy seniors was obtained
at various senior centers and/or senior living communities within the Brevard
County area, which included Greater Palm Bay Senior Center, Wickham Park
Senior Center, Martin Anderson Senior Center, and North Brevard Senior Center.
Exclusion criteria included individuals who have had some type of brain injury,
neurological disorder, or diagnosis of cognitive impairment. It is important to note
that these individuals were not seeking an evaluation due to memory concerns;
rather, they were recruited solely for the purpose of research participation.
Inclusion criteria included age equal to or greater than 65 and a score on the
Montreal Cognitive Assessment (MoCA) greater than 23. This cutoff score was
used instead of the recommended score of 26 due to a meta-analysis which revealed
a score of 23/30 allowed for the best diagnostic accuracy (Carson et al., 2018). The
original score of 26/30 has shown to lead to an inflated rate of false positives. A
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false positive would be an individual considered to have some type of cognitive
impairment because they scored below 26; however, because the cutoff score is
considered to be high, the individual would not actually have cognitive
impairments (Carson et al., 2018).
Participants who met these inclusion criteria were informed of all study
procedures and protocols, and then asked to give consent prior to initiation of
testing. Once the informed consent was obtained, participants were asked to fill out
demographic information and then complete the MoCA, followed by a short battery
of cognitive tests that would assess different areas of cognitive functioning such as
language, memory and learning, executive functioning, attention and concentration,
motor and processing speed, and visual-spatial skills. The total time of testing was
about an hour. In exchange for their participation, participants were compensated
with $25.00.
Individuals who were considered cognition within normal limits and
diagnosed with MCI or AD were patients from HFMDC who were referred for an
evaluation due to memory concerns and subsequently underwent a formal interview
with a geriatrician and licensed clinical social worker. During this interview period,
the MoCA was administered. If the geriatrician wanted diagnostic clarity, the
patient was recommended to undergo neuropsychological testing. A brief
neuropsychological examination (BNE) was administered by a clinical psychology
doctoral student under the supervision of a board-certified licensed clinical
neuropsychologist. A consent form was signed by the patient on the day of their
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evaluation, which gave permission for their de-identified test data to be used for
future research purposes. After the informed consent was signed, patients
underwent a BNE to assess different areas of cognitive functioning including
language, memory and learning, executive functioning, attention and concentration,
processing speed, visuospatial skills, and basic adaptive functioning skills. Testing
was administered in English, and the total time of the BNE took approximately 2
hours.
Once testing was completed, a multi-disciplinary case review developed
diagnostic impressions and recommendations based on the data presented for each
patient. These case review meetings include a geriatrician, social worker,
neuropsychologist, neurologist, pharmacy doctoral students, and clinical
psychology doctoral students. Diagnostic impressions were based on the overall
presentation of evaluation of data including psychosocial history, onset of memory
loss, medical history, review of neuropsychological test data, and brain imaging if
available. The multi-disciplinary team would diagnose patients according to the
Tenth Revision of the International Classification of Diseases and Related Health
Problems (ICD-10; WHO, 1992). The MCI group included both amenstic and nonamnestic types, and this was based on the Peterson (2004) criteria.
Research Design and Analysis of Data
Prior to analyzing data, the researcher obtained approval from the Florida
Institute of Technology Review Board (IRB). Additionally, permission was granted
to the researcher by the Health First Memory Disorder Clinic to utilize their
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research database. Informed consent was also obtained prior to each participant
completing their neuropsychological evaluation or before their research study
participation.
Means, standard deviations, and frequencies for patient demographics will
be obtained utilizing descriptive statistics. An independent samples t-test will be
conducted to examine performance differences on delayed verbal recall total scores
on the MoCA and SVLT. An ordinal logistic regression will be utilized to
examined delayed recall total scores for the MoCA and SVLT regarding healthy
controls, MCI individuals, and AD individuals. This data will be analyzed using
Statistical Package for the Social Sciences (SPSS)-Version 25.
Although the MoCA allows for brevity and insight into an individual’s
performance within several cognitive domains, it does not allow for an in-depth
analysis of an individual’s potential cognitive shortcomings. Further diagnostic
clarity is almost always warranted when a performance on a MoCA is below
average; however, time constraints may cause health professionals to opt for the
results from the brief and convenient MoCA. The significance of this study allows
for analysis of another brief assessment, the SVLT, which can presumably provide
further diagnostic clarity and potentially less false positives in comparison to the
MoCA when looking at list learning performance and potential amnestic MCI
diagnosis.
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Chapter 10 Results
Healthy Community Controls and Healthy HFMDC Controls
Assumption tests suggested that there were no outliers in the mean wordlist
delayed recall total scores on the MoCA for healthy controls from the community
and healthy controls from HFMDC, and mean wordlist delayed recall total scores
on the MoCA was normally distributed. Levene’s test suggested that variances in
mean wordlist delayed recall total scores on the MoCA for healthy controls from
the community and healthy controls from HFMDC were statistically equivalent, F
(299) = .37, p = .55.
An independent-samples t-test was performed to compare mean wordlist
delayed recall total scores on the MoCA from healthy controls within the
community and healthy controls from HFMDC. Results from 301 individuals (249
healthy community controls, 52 healthy controls from HFMDC) showed that
healthy controls within the community (M = 3.01, SD = 1.30) were not significantly
different from healthy controls at HFMDC (M = 3.02, SD = 1.35) on their wordlist
delayed recall total scores on the MoCA, t(299) = .036, p = .486, with the
difference to have a 95% CI [-.39, .40]. The difference presents a small-sized
effect, Cohen’s d = 0.0008. Due to the insignificant difference between these
separate groups, healthy community controls were analyzed as well as a combined
group of healthy controls from both the community and HFMDC after the
hypothesis testing.
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Assumption tests suggested that there were no outliers in the mean wordlist
delayed recall total scores on the SVLT for healthy controls from the community
and healthy controls from HFMDC, and mean wordlist delayed recall total scores
on the SVLT was normally distributed. Levene’s test suggested that variances in
mean wordlist delayed recall total scores on the SVLT for healthy controls from the
community and healthy controls from HFMDC were statistically equivalent, F
(299) = 2.41, p = .122.
An independent-samples t-test was performed to compare mean wordlist
delayed recall total scores on the SVLT from healthy controls within the
community and healthy controls from HFMDC. Results from 301 individuals (249
healthy community controls, 52 healthy controls from HFMDC) showed that
healthy controls within the community (M = 6.73, SD = 2.23) were not significantly
different from healthy controls at HFMDC (M = 6.44, SD = 1.87) on their wordlist
delayed recall total scores on the SVLT, t(299) = -.87, p = .193, with the difference
to have a 95% CI [-.94, .36]. The difference presents a small-sized effect, Cohen’s
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d = 0.14. Due to the insignificant difference between these separate groups, healthy
community controls were not used in subsequent analyses regarding the SVLT.

Descriptive Statistics
The final sample consisted of 391 participants, included 48.8% of
individuals diagnosed with AD (n = 191), 37.9% of individuals diagnosed with
MCI (n = 148), and 13.3% individuals who were considered cognition within
normal limits (n = 52). The sample included 57.0% participants who were females
(n = 223) and 43.0% of whom were males (n = 168). Participants’ ages ranged from
65 to 97 at the time of their initial evaluation (M = 82.33, SD = 6.14). Participants’
highest level of education ranged from 5 to 20 years (M = 13.71, SD = 2.63. Most
of the sample identified as Caucasian (n = 362; 92.6%), followed by African
American (n = 19; 4.9%), and Asian (n = 3; 0.8%). A small number of participants
selected “Other” as their race (n = 2; 0.5%) or chose not to respond (n = 4; 1.0%).
In terms of ethnicity, participants were mostly non-Hispanic (n = 337; 96.4%),
followed by Hispanic ethnicity (n = 14; 3.6%). Participants’ demographic
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information was collected and documented at the time of their initial evaluation
through self-report and/or their electronic medical record (EMR).

MoCA Wordlist Performance for Healthy HFMDC Controls and MCI
Patients
Assumption tests suggested that there were no outliers in the mean wordlist
delayed recall total scores on the MoCA for healthy controls from HFMDC and
individuals diagnosed with MCI from HFMDC, and mean wordlist delayed recall
total scores on the MoCA was normally distributed. Levene’s test suggested that
variances in mean wordlist delayed recall total scores on the MoCA for healthy
controls from HFMDC and individuals diagnosed with MCI from HFMDC were
statistically equivalent, F (198) = 2.01, p = .16.
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An independent-samples t-test was performed to compare mean wordlist
delayed recall total scores on the MoCA from healthy controls from HFMDC and
individuals diagnosed with MCI from HFMDC. Results from 200 patients (52
healthy controls, 148 MCI patients) showed that MCI patients (M = 1.24, SD =
1.50) were significantly different from healthy controls (M = 3.02, SD = 1.35) on
their wordlist delayed recall total scores on the MoCA, t(198) = -7.73, p <.001,
with the difference to have a 95% CI [-2.24, -1.33]. The difference presents a largesized effect, Cohen’s d = 1.27. Hypothesis #1 those healthy controls and
individuals diagnosed with MCI will have similar wordlist delayed recall total
scores on the MoCA was not supported.

SVLT Wordlist Performance for Healthy HFMDC Controls and MCI Patients
Assumption tests suggested that there were no outliers in the mean delayed
recall total scores on the SVLT for healthy controls from HFMDC and individuals
diagnosed with MCI from HFMDC and mean delayed recall total scores on the
SVLT was normally distributed. Levene’s test suggested that variances in mean
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delayed recall total scores on the SVLT for healthy controls from HFMDC and
individuals diagnosed with MCI from HFMDC were statistically equivalent, F
(198) = 2.61, p = .11.
An independent-samples t-test was performed to compare mean delayed
total scores on the SVLT from healthy controls at HFMDC and patients diagnosed
with MCI at HFMDC. Results from 200 patients (52 healthy controls, 148 MCI
patients) showed that healthy controls (M = 6.44, SD = 1.87) were significantly
higher than MCI patients (M = 3.70, SD = 2.26) on their delayed recall total scores
on the SVLT, t(198) = -7.84, p <.001, with the difference to have a 95% CI [-3.43,
-2.05]. The difference presents a large-sized effect, Cohen’s d = 1.32. Hypothesis
#2 those healthy controls will have higher delayed recall total scores on the SVLT
than individuals diagnosed with MCI was supported.

MoCA and SVLT Performance in AD Patients
Assumption tests suggested that there were outliers in the mean wordlist
delayed recall total scores on the MoCA for healthy controls from HFMDC and
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individuals diagnosed with AD from HFMDC, and mean wordlist delayed recall
total scores on the MoCA was not normally distributed. Levene’s test suggested
that variances in mean wordlist delayed recall total scores on the MoCA for healthy
controls from HFMDC and individuals diagnosed with AD from HFMDC were not
statistically equivalent, F (198) = 85.40, p < .001.
An independent-samples t-test was performed to compare the mean wordlist
delayed recall total scores on the MoCA in healthy controls and patients diagnosed
with AD. Results from 243 patients (52 healthy controls, 191 AD) showed that
healthy controls (M = 3.02, SD = 1.35) were significantly higher than AD patients
(M = .19, SD = .56) on their wordlist delayed recall total scores on the MoCA,
t(55.83) = -14.78, p < .001, with the differences to have a 95% CI [-3.23, -2.45].
The difference presents a large-sized effect, Cohen’s d = 2.74.

Assumption tests suggested that there were outliers in the mean wordlist
delayed recall total scores on the SVLT for healthy controls from HFMDC and
individuals diagnosed with AD from HFMDC, and mean wordlist delayed recall
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total scores on the SVLT were not normally distributed. Levene’s test suggested
that variances in mean wordlist delayed recall total scores on the SVLT for healthy
controls from HFMDC and individuals diagnosed with AD from HFMDC were not
statistically equivalent, F (241) = 16.35, p < .001.
An independent-samples t-test was performed to compare the mean delayed
recall total scores on the SVLT in healthy controls and patients diagnosed with AD.
Results from 243 patients (52 healthy controls, 191 AD) showed that healthy
controls (M = 6.44, SD = 1.87) were significantly higher than AD patients (M = .88,
SD = 1.24) on their delayed recall total scores on the SVLT, t(63.58) = -20.25, p <
.001, with the differences to have a 95% CI [-6.11, -5.01]. The difference presents a
large-sized effect, Cohen’s d = 3.5.

Assumption tests suggested that there were outliers in the mean wordlist
delayed recall total scores on the MoCA for individuals diagnosed with MCI from
HFMDC and individuals diagnosed with AD from HFMDC, and mean wordlist
delayed recall total scores on the MoCA were not normally distributed. Levene’s
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test suggested that variances in mean wordlist delayed recall total scores on the
MoCA for individuals diagnosed with MCI from HFMDC and individuals
diagnosed with AD from HFMDC were not statistically equivalent, F (337) =
216.90, p < .001.
An independent-samples t-test was performed to compare the mean wordlist
delayed recall total scores on the MoCA in MCI patients and patients diagnosed
with AD. Results from 339 patients (148 MCI, 191 AD) showed that MCI patients
(M = 1.24, SD = 1.46) were significantly higher than AD patients (M = .19, SD =
.56) on their wordlist delayed recall total scores on the MoCA, t(180.7) = -8.28, p <
.001, with the differences to have a 95% CI [-1.30, -.80]. The difference presents a
large-sized effect, Cohen’s d = .95.

Assumption tests suggested that there were outliers in the mean wordlist
delayed recall total scores on the SVLT for individuals diagnosed with MCI from
HFMDC and individuals diagnosed with AD from HFMDC, and mean wordlist
delayed recall total scores on the SVLT were not normally distributed. Levene’s
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test suggested that variances in mean wordlist delayed recall total scores on the
SVLT for individuals diagnosed with MCI from HFMDC and individuals
diagnosed with AD from HFMDC were not statistically equivalent, F (337) = 14.67, p < .001.
An independent-samples t-test was performed to compare the mean wordlist
delayed recall total scores on the SVLT in MCI patients and patients diagnosed
with AD. Results from 339 patients (148 MCI, 191 AD) showed that MCI patients
(M = 3.70, SD = 2.26) were significantly higher than AD patients (M = .88, SD =
1.24) on their wordlist delayed recall total scores on the SVLT, t(214.12) = -13.69,
p < .001, with the difference to have a 95% CI [-3.23, -2.41]. The difference
presents a large-sized effect, Cohen’s d = 1.55. Combined, these analyses support
hypothesis #3 those individuals diagnosed with AD will have lower delayed recall
total scores on both the MoCA and the SVLT compared to healthy controls and
individuals diagnosed with MCI.
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MoCA Performance and Severity of Cognitive Impairment
An ordinal logistic regression was conducted to predict more severe
cognitive impairment based on diagnosis (HFMDC healthy, MCI, AD), based on
participant’s performance on the wordlist recall scores on the MoCA. A decrease in
MoCA delayed recall on the wordlist was associated with an increase in the odds of
poorer cognition based on diagnosis, with an odds ratio of 2.92 (95% CI, 2.41 to
3.52), Wald χ2(1) = 123.110, p < .001.
SVLT Performance and Severity of Cognitive Impairment
An ordinal logistic regression was conducted to predict more severe
cognitive impairment based on diagnosis (HFMDC healthy, MCI, AD), based on
participant’s performance on the SVLT delayed recall. A decrease in SVLT
delayed recall was associated with an increase in the odds of poorer cognition
based on diagnosis, with an odds ratio of 2.27 (95% CI, 2.01 to 2.58), Wald χ2(1) =
166.054, p < .001
MoCA and SVLT Performance in Amnestic MCI and Non-amnestic MCI
Assumption tests suggested that there were outliers in the mean wordlist
delayed recall total scores on the MoCA for individuals diagnosed with amnestic
MCI and non-amnestic MCI, and mean wordlist delayed recall total scores on the
MoCA were not normally distributed. Levene’s test suggested that variances in
mean wordlist delayed recall total scores on the MoCA for individuals diagnosed
with amnestic MCI and individuals diagnosed with non-amnestic MCI were not
statistically equivalent, F (146) = -6.48, p < .001.
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An independent-samples t-test was performed to compare the mean wordlist
delayed recall total scores on the MoCA in amnestic MCI patients and nonamnestic MCI patients. Results from 148 patients (109 amnestic MCI, 39 nonamnestic MCI) showed that non-amnestic MCI patients (M = 2.38, SD = 1.63) were
significantly higher than amnestic MCI patients (M = .83, SD = 1.15) on their
wordlist delayed recall total scores on the MoCA, t(52) = -5.50, p < .001, with the
difference to have a 95% CI [-2.13, -.99]. The difference presents a large-sized
effect, Cohen’s d = 1.10. The hypothesis that there would be no difference in
MoCA wordlist performance in amnestic MCI and non-amnestic MCI was not
supported. This finding, though, does explain and provide evidence for why the
first hypothesis was not supported, as there were significantly more amnestic MCI
patients in the total sample. this may have contributed to why the MoCA delayed
recall scores in the total MCI group were so poor in comparison to individuals with
normal cognition.

Assumption tests suggested that there were no outliers in the mean wordlist
delayed recall total scores on the SVLT for individuals diagnosed with amnestic
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MCI and non-amnestic MCI, and mean wordlist delayed recall total scores on the
SVLT were normally distributed. Levene’s test suggested that variances in mean
wordlist delayed recall total scores on the SVLT for individuals diagnosed with
amnestic MCI and individuals diagnosed with non-amnestic MCI were statistically
equivalent, F (146) = .90, p = .34.
An independent-samples t-test was performed to compare the mean wordlist
delayed recall total scores on the SVLT in amnestic MCI patients and non-amnestic
MCI. Results from 148 patients (109 amnestic MCI, 39 non-amnestic MCI) showed
that non-amnestic MCI patients (M = 5.82, SD = 1.78) were significantly higher
than amnestic MCI patients (M = 2.94, SD = 1.91) on their wordlist delayed recall
total scores on the SVLT, t(146) = -8.22, p < .001, with the difference to have a
95% CI [-3.57, -2.18]. The difference presents a large-sized effect, Cohen’s d =
1.56. The hypothesis that there would be a difference on the SVLT in patients
diagnosed with amnestic MCI and non-amnestic MCI was supported.
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MoCA and SVLT Performance in Within Normal Limits and Non-amnestic
MCI
Assumption tests suggested that there were no outliers in the mean wordlist
delayed recall total scores on the MoCA for individuals who were within normal
limits and non-amnestic MCI, and mean wordlist delayed recall total scores on the
MoCA was normally distributed. Levene’s test suggested that variances in mean
wordlist delayed recall total scores on the MoCA for individuals within normal
limits and patients diagnosed with non-amnestic MCI were statistically equivalent,
F (89) = 2.55, p = .11.
An independent-samples t-test was performed to compare the mean wordlist
delayed recall total scores on the MoCA in individuals who performed within
normal limits and non-amnestic MCI patients. Results from 91 patients (52 within
normal limits, 39 non-amnestic MCI) showed that individuals who performed
within normal limits (M = 3.02, SD = 1.35) were significantly higher than nonamnestic MCI patients (M = 2.38, SD = 1.63) on their wordlist delayed recall total
scores on the MoCA, t(89) = 2.03, p = .046, with the difference to have a 95% CI
[.01, 1.25]. The difference presents a small to medium-sized effect, Cohen’s d =
0.43.
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Assumption tests suggested that there were no outliers in the mean wordlist
delayed recall total scores on the SVLT for individuals who performed within
normal limits and non-amnestic MCI, and mean wordlist delayed recall total scores
on the SVLT was normally distributed. Levene’s test suggested that variances in
mean wordlist delayed recall total scores on the SVLT for individuals who
performed within normal limits and individuals diagnosed with non-amnestic MCI
were statistically equivalent, F (89) = .89, p = .35.
An independent-samples t-test was performed to compare the mean wordlist
delayed recall total scores on the SVLT in individuals who performed within
normal limits and non-amnestic MCI patients. Results from 91 patients (52 within
normal limits, 39 non-amnestic MCI) showed that there was no a significant
difference between individuals who performed within normal limits (M = 6.44, SD
= 1.87) and non-amnestic MCI patients (M = 5.82, SD = 1.78) on their wordlist
delayed recall total scores on the SVLT, t(89) = 1.60, p = .11, with the difference to
have a 95% CI [-.15, 1.39]. The difference presents a small to medium-sized effect,
Cohen’s d = 0.33. The hypothesis that individuals who performed within normal
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limits and patients who were diagnosed with non-amnestic MCI will have similar
scores on the MoCA wordlist, but not the SVLT, was not supported.

MoCA and SVLT Wordlist Performance for Combined Healthy Controls and
MCI Patients
Assumption tests suggested that there were outliers in the mean wordlist
delayed recall total scores on the MoCA for combined healthy controls and
individuals diagnosed with MCI from HFMDC, and mean wordlist delayed recall
total scores on the MoCA were not normally distributed. Levene’s test suggested
that variances in mean wordlist delayed recall total scores on the MoCA for
combined healthy controls and individuals diagnosed with MCI from HFMDC
were not statistically equivalent, F (447) = 8.67, p = .003.
An independent-samples t-test was performed to compare mean wordlist
delayed recall total scores on the MoCA from combined healthy controls and
individuals diagnosed with MCI from HFMDC. Results from 449 patients (301
combined healthy controls, 148 MCI patients) showed that MCI patients (M = 1.24,
SD = 1.50) were significantly different from combined healthy controls (M = 3.01,
SD = 1.31) on their wordlist delayed recall total scores on the MoCA, t(266) = -
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12.54, p <.001, with the difference to have a 95% CI [-2.06, -1.50]. The difference
presents a large-sized effect, Cohen’s d = 1.26.
Assumption tests suggested that there were no outliers in the mean delayed
recall total scores on the SVLT for combined healthy controls and individuals
diagnosed with MCI from HFMDC and mean delayed recall total scores on the
SVLT was normally distributed. Levene’s test suggested that variances in mean
delayed recall total scores on the SVLT for combined healthy controls and
individuals diagnosed with MCI from HFMDC were statistically equivalent, F
(447) = .28, p = .60.
An independent-samples t-test was performed to compare mean delayed
recall total scores on the SVLT from combined healthy controls and patients
diagnosed with MCI at HFMDC. Results from 449 patients (301 combined healthy
controls, 148 MCI patients) showed that combined healthy controls (M = 6.68, SD
= 2.18) were significantly higher than MCI patients (M = 3.70, SD = 2.26) on their
delayed recall total scores on the SVLT, t(447) = -13.46, p <.001, with the
difference to have a 95% CI [-3.41, -2.54]. The difference presents a large-sized
effect, Cohen’s d = 1.34.

MoCA and SVLT Performance in Combined Healthy Controls and AD
Patients
Assumption tests suggested that there were outliers in the mean wordlist
delayed recall total scores on the MoCA for combined healthy controls and
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individuals diagnosed with AD from HFMDC, and mean wordlist delayed recall
total scores on the MoCA was not normally distributed. Levene’s test suggested
that variances in mean wordlist delayed recall total scores on the MoCA for
combined healthy controls and individuals diagnosed with AD from HFMDC were
not statistically equivalent, F (490) = -28.23, p < .001.
An independent-samples t-test was performed to compare the mean wordlist
delayed recall total scores on the MoCA in combined healthy controls and patients
diagnosed with AD. Results from 492 patients (301 combined healthy controls, 191
AD) showed that combined healthy controls (M = 3.01, SD = 1.31) were
significantly higher than AD patients (M = .19, SD = .56) on their wordlist delayed
recall total scores on the MoCA, t(439.62) = -33.01, p < .001, with the differences
to have a 95% CI [-2.99, -2.66]. The difference presents a large-sized effect,
Cohen’s d = 2.80.
Assumption tests suggested that there were outliers in the mean wordlist
delayed recall total scores on the SVLT for combined healthy controls and
individuals diagnosed with AD from HFMDC, and mean wordlist delayed recall
total scores on the SVLT were not normally distributed. Levene’s test suggested
that variances in mean wordlist delayed recall total scores on the SVLT for
combined healthy controls and individuals diagnosed with AD from HFMDC were
not statistically equivalent, F (490) = -33.57, p < .001.
An independent-samples t-test was performed to compare the mean delayed
recall total scores on the SVLT in combined healthy controls and patients
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diagnosed with AD. Results from 492 patients (301 combined healthy controls, 191
AD) showed that combined healthy controls (M = 6.68, SD = 2.18) were
significantly higher than AD patients (M = .88, SD = 1.24) on their delayed recall
total scores on the SVLT, t(484.79) = -37.67, p < .001, with the differences to have
a 95% CI [-6.10, -5.50]. The difference presents a large-sized effect, Cohen’s d =
3.27.

MoCA and SVLT Performance in Combined Within Normal Limits and Nonamnestic MCI
Assumption tests suggested that there were outliers in the mean wordlist
delayed recall total scores on the MoCA for the combined group of individuals who
were within normal limits and non-amnestic MCI, and mean wordlist delayed recall
total scores on the MoCA was normally distributed. Levene’s test suggested that
variances in mean wordlist delayed recall total scores on the MoCA for individuals
within normal limits and patients diagnosed with non-amnestic MCI were not
statistically equivalent, F (338) = 5.98, p = .01.
An independent-samples t-test was performed to compare the mean wordlist
delayed recall total scores on the MoCA in the combined group of individuals who
performed within normal limits and non-amnestic MCI patients. Results from 340
patients (301 combined within normal limits, 39 non-amnestic MCI) showed that
combined group of individuals who performed within normal limits (M = 3.01, SD
= 1.31) were significantly higher than non-amnestic MCI patients (M = 2.38, SD =
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1.63) on their wordlist delayed recall total scores on the MoCA, t(44.56) = -2.31, p
= .026, with the difference to have a 95% CI [-1.18, -.08]. The difference presents a
small to medium-sized effect, Cohen’s d = 0.42.
Assumption tests suggested that there were outliers in the mean wordlist
delayed recall total scores on the SVLT for the combined group of individuals who
performed within normal limits and non-amnestic MCI, and mean wordlist delayed
recall total scores on the SVLT was normally distributed. Levene’s test suggested
that variances in mean wordlist delayed recall total scores on the SVLT for
individuals who performed within normal limits and individuals diagnosed with
non-amnestic MCI were not statistically equivalent, F (338) = 5.19, p = .02.
An independent-samples t-test was performed to compare the mean wordlist
delayed recall total scores on the SVLT in the combined group of individuals who
performed within normal limits and non-amnestic MCI patients. Results from 340
patients (301 combined healthy controls, 39 non-amnestic MCI) showed that
combined healthy controls (M = 6.68, SD = 2.18) were significantly higher than
non-amnestic MCI patients (M = 5.82, SD = 1.78) on their delayed recall total
scores on the SVLT, t(53.96) = -2.77, p = .01, with the differences to have a 95%
CI [-1.48, -.24]. The difference presents a small to medium-sized effect, Cohen’s d
= 0.43.
Chapter 11 Discussion
Gaining insight into the diagnostic capabilities of well-known cognitive
measures is integral to the field of clinical neuropsychology. Additionally, it is also
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imperative to identify the diagnostic capabilities of new assessments being
developed and utilized for diagnostic purposes. Determining a diagnosis correctly
allows patients to be presented with the correct resources and treatment plan while
following up with the potential progression of their disorder. Also, with advances
in medicine, there can be specific treatments for certain diagnoses, which again
illustrates why making the correct diagnosis in the first place is extremely
important.
Normative data is typically acquired by administering assessments to
individuals who are not showing signs of cognitive impairment. One of the most
effective ways to gather normative data is from healthy volunteers within
community settings. Although data can also be obtained from individuals
undergoing cognitive testing in a medical setting who are ultimately diagnosed with
normal cognition, most of these individuals or their families have expressed
concerns regarding cognitive issues, suggesting that they might be “different” in
some way compared to individuals from community settings. In the current study,
it was predicted that the memory performance of individuals collected within the
community would be significantly different when compared to the individuals
diagnosed with normal cognition at the HFMDC. However, the results showed
there was not a significant difference between these two groups. This suggests that
it might be reasonable to consider data collected from individuals who were
evaluated for a possible memory disorder but diagnosed as having normal cognition
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as normative data. Having a greater sample of normative data might in turn allow
for even greater diagnostic precision.
No significant differences were found on the wordlist delayed recall scores
from the MoCA between healthy controls and individuals diagnosed with MCI.
Due to the MoCA having a relatively short word list containing only 5 words, it
was hypothesized that it did not have the breadth to clearly differentiate healthy
controls and individuals diagnosed with MCI. This hypothesis was not supported,
indicating that the MoCA is an adequate tool to potentially detect MCI. However, it
should be noted that the majority of patients in the MCI group were amnestic
(around 74%), and individuals with amnestic MCI typically exhibit prominent
memory issues. Indeed, individuals with amnestic MCI performed worse on the
MoCA word list than individuals with non-amnestic MCI. This may have
potentially skewed average scores on both measures in the overall MCI group
toward suggesting more prominent memory deficits, which may not have been
observed if the relative proportions of individuals with amnestic MCI and nonamnestic MCI were more evenly distributed.
Prior research has suggested this as well. For example, Kaur et al. (2018)
compared two measures of delayed recall including both the MoCA and the Craft
Story 21 and found the MoCA’s memory index score was better at discriminating
normal cognition from amnestic MCI than the Craft Story. Further research would
be beneficial to find what score on the MoCA wordlist is likely indicative of MCI
specifically amnestic MCI. This is an important finding because it also supports
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previous literature about the MoCA being an adequate tool to detect cognitive
changes. Furthermore, it could aid in follow up if the person were to engage in a
neuropsychological evaluation. In many instances patients are only interacting with
doctors briefly, and especially with how integrated clinical psychology is becoming
with overall healthcare, a brief measure to identify cognitive changes would be
ideal, such as the MoCA. Additionally, if the MoCA provides an adequate
prediction of the neuropsychological difficulties an individual may possess, the
neuropsychologist can tailor their battery to the deficits indicated on the MoCA.
Differences in delayed recall total scores on the SVLT were observed
between healthy controls at HFMDC and patients diagnosed with MCI at HFMDC.
This finding is important, because it indicates the SVLT is an adequate tool for
differentiating cognitive changes in verbal memory between those who do not
present with a cognitive decline and those who are having a cognitive decline. As
mentioned previously, the SVLT is a measure that was created at the HFMDC. It is
brief but provides a detailed amount of information regarding learning, encoding,
and recall with respect to verbal memory. Although not as brief as the MoCA, it is
still a brief tool that also provides more detailed information than the MoCA. It is a
useful assessment, only taking about 10 minutes in total to administer. It appears to
be a useful tool to include in neuropsychological batteries, especially in evaluating
individuals where concerns regarding memory functioning are present.
A significant difference was also found between healthy controls and
individuals diagnosed with AD in relation to their performance on the MoCA
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wordlist. This finding was not surprising; usually individuals with AD are already
showing prominent cognitive deficits. It would be expected for there to be a
significant difference on the wordlist on the MoCA in individuals who are healthy,
and those individuals diagnosed with AD, primarily based on the severity of
impairment in those with AD. Additionally, there was also a significant difference
on delayed recall total scores on the SVLT in healthy controls and patients
diagnosed with AD. As described previously, the SVLT is a somewhat expanded
verbal memory test compared to the wordlist on the MoCA.
Additionally, there was also a significant difference found when comparing
the mean wordlist delayed recall total scores on the MoCA in MCI patients and
patients diagnosed with AD. This finding is important due to the diagnostic
implications regarding these diagnoses. When an individual has MCI, they are
better able to maintain the ability to independently perform most activities of daily
living, while those diagnosed with AD are unable to perform many of these tasks
(Jongsiriyanyong & Limpawattana, 2018). This distinction is critical in determining
follow up care and coordination of services. There was also a significant difference
found when comparing the mean wordlist delayed recall total scores on the SVLT
in MCI patients and patients diagnosed with AD. This is an important finding for
many of the reasons previously detailed as well as the SVLT being utilized for
diagnostic purposes. Differences on the performances of the SVLT wordlist can
differentiate MCI from AD, and due to the different prognoses MCI and AD have,
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this finding is helpful in knowing that performance on the SVLT is significantly
different in these separate populations.
It was also found that MoCA wordlist performance can predict more severe
cognitive impairment in regard to diagnosing healthy, MCI, and AD. This finding
means that the lower the MoCA delayed recall on the wordlist was, there was an
increase in the odds of poorer cognition based on diagnosis. This finding was
similar to what was found regarding the SVLT. Regarding the MoCA, this finding
is important because although it is a screener, performance on delayed recall can
differentiate potential MCI and AD. However, this finding carries more weight
regarding the SVLT because the SVLT is used for actual diagnostic purposes.
Analyses also showed that performance on the MoCA wordlist and the
SVLT wordlist were significantly higher in individuals with non-amnestic MCI
patients when compared to amnestic MCI patients. This did not support the fifth
hypothesis, as it was predicted there would be a significant difference on the SVLT
and not the MoCA. What this suggests is that both the MoCA and SVLT are
adequate measures for determining memory difficulties, even in the potentially
more subtle memory presentations often observed with amnestic MCI.
Furthermore, it was found that there was a significant difference between
individuals who performed within normal limits and non-amnestic MCI patients on
the MoCA wordlist. However, there was a difference, but not a significant
difference, between individuals who performed within normal limits and nonamnestic MCI patients on the SVLT wordlist. This suggests that although there was
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a significant difference regarding the MoCA, the non-significance difference on the
SVLT may suggest that individuals who perform within normal limits and nonamnestic MCI patients may have similar performances on verbal memory tasks.
This would likely be due to individuals who performed within normal limits and
non-amnestic MCI patients still having intact verbal memory with potential deficits
in other areas for non-amnestic MCI patients. The significant difference regarding
the MoCA is likely due to the potential limited capacity it has in differentiating
memory changes.
It can be difficult for aging individuals to know when they are experiencing
normal aging, or if they are exhibiting signs of a meaningful cognitive decline.
Collecting normative data in geriatric individuals is important because there are
known age-related cognitive changes that do not constitute a clinically meaningful
decline or impairment. Earlier detection of potential dementia processes better aids
in positive outcomes and continuity of care. In a 2019 study conducted by Nakahori
et al., it was found that both older adults and family members were aware of the
individual’s forgetfulness, which can often be a sign of normal aging. However,
this may also be a symptom of potential cognitive decline. In this study, family
members appeared more aware of forgetfulness as a potential symptom in
comparison to the older adults themselves. Overall, it appeared there was a
discrepancy in cognitive decline between older adults and their family members
(Nakahori et al., 2019). This is telling in that older adults may not be aware of their
potential cognitive decline or are avoiding addressing it. This encourages the idea
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of early education about neuropsychology in older adults and pushing for early
cognitive testing before cognitive decline. Cognitive testing would be beneficial in
being implemented as a yearly checkup, much like when individuals have yearly
checkups regarding other aspects of their health.
Overall, it appears the MoCA and SVLT are both adequate measures for
differentiating memory impairments among healthy controls, MCI patients, and AD
patients. Specifically, it appears the MoCA is adequate in detecting memory
declines even among those experiencing milder memory impairments that are
clinically meaningful but do not constitute AD. In the future, it would be beneficial
to see if the MoCA is also successful at identifying cognitive changes in those
without memory issues but maybe executive or language difficulties. Although the
MoCA could potentially be adequate and sufficient for determining potential
memory issues, a more comprehensive battery of assessments would be important
to administer to determine what other cognitive changes are present toward
providing greater overall diagnostic accuracy.
Additionally, it may be that the MoCA is over pathologizing individuals.
Although it is essentially a triage measure, the MoCA cut score may be too high to
indicate cognitive impairment. In a study conducted by Dautzenberg & Beekman in
2020, it was found that a cut score of 21 or above would be the “best” cutoff score,
as those with scores above this are likely not indicative of dementia. Thus, if this
cutoff score would be used, it could reduce referrals to memory clinics or other
neuropsychological testing centers by 50% (Dautzenber & Beekman, 2020).
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However, one could argue that it may be beneficial to use a higher cut-off score
even if that results in having more false positives, as it would be better to overinclusive in identifying a possible memory concern. Furthermore, a screening
measure that identifies an individual as having possible cognitive impairment that
is ultimately diagnosed within normal limits might be better than one that fails to
identify clinically meaningful cognitive impairment by having too low of a cut-off
score that overlooks mild cognitive changes. Given that these mild cognitive
changes could potentially be indicative of an underlying progressive
neurodegenerative process, the risk of failing to identify them early in the course of
the disease appears to be too great.
With that, the SVLT could be utilized when examining the learning and
memory domain compared to other domains. Different neurodegenerative
disorders, including those disorders associated with aging, have different
presentations, and although the MoCA seems to be capable of showing cognitive
changes regarding verbal memory, there are many other nuances in diagnosis with
neurodegenerative disorders. For example, individuals with vascular dementia tend
to exhibit more of a disturbance to frontal lobe functions with less of a deficit in
verbal memory impairment (Sachdev et al., 2004). Specifically, individuals with
vascular dementia are more likely to have difficulties with abstraction, mental
flexibility, information processing speed, and working memory (Sachdev et al.,
2004). If an individual with vascular dementia were administered the MoCA, some
impairments may be noticeable; however, performance on the MoCA alone may be
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insufficient to justify a diagnosis. A comprehensive battery of cognitive
assessments would provide more information to assist with differential diagnosis,
while looking for an overall pattern which may be suggestive of vascular dementia.
Additionally, individuals with frontotemporal lobar degeneration, or frontotemporal
dementia, typically present with deficits in the language and attention or executive
functioning domains, with memory impairments being less severe when compared
to AD (Yoshizama et al., 2013). Similarly, the MoCA would likely be insufficient
to differentiate these conditions in many cases due to its brevity, whereas a pattern
of relative strengths and weaknesses across cognitive domains is often better
observed when conducting a more comprehensive assessment.
Nevertheless, the MoCA appears to be capable of identifying memory
impairments in those with amnestic MCI and AD. In the future, though, it would be
important to explore whether other sections of the MoCA correspond with other
cognitive domains (e.g., attention, language), and subsequently how well the
MoCA is able to screen for other neurodegenerative diseases with less of a memory
impairment. As mentioned previously, other neurodegenerative disorders have
more prominent deficits in different domains other than memory.
Chapter 12 Limitations
There are several limitations within this current study. One of these
limitations is the lack of diversity. However, this issue appears present in many
settings related to neuropsychology. For example, a survey was sent out by
Elbulok-Charcape et al., in 2014 to 2,178 neuropsychologists in the United States
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and Canada with 512 surveys being returned for analysis. It was reported that 66%
of their patients were white, 15.7% of their patients were black, 11.7% of their
patients were Hispanic/Latino, and 4.2% of their patients were Asian. There were
several suggestions in this study to work towards fixing the lack of representation
in the field of neuropsychology. This included educating people at a younger age
about neuropsychology at a younger age as well as increasing diversity in
neuropsychology research (Elbulok-Charcape et al., 2014).
Another limitation in this current study is the lack of research on sensitivity
and specificity of the SVLT. Although the SVLT is used as a diagnostic tool for
determining whether someone is healthy, has MCI, or had AD, research into its
sensitivity and specificity has not yet been determined. This study was created to
widen the knowledge on this measure and appeared to align with the results that are
determined by the MoCA, more knowledge on the SVLT would have been
beneficial for comparison.
Another limitation in this current study is regarding the individual’s data
from HFMDC. The obtainment of the MoCA data and SVLT data would have been
beneficial if administered by the same individual, and the MoCA and SVLT were
administered by different people and on different days. There are a variety of
factors as to how different examiners and being examined on different days can
affect performance.
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Chapter 13 Conclusions
Screening measures and diagnostic tools are extremely important when
evaluating cognitive difficulties or changes. It appears the MoCA is a capable
screening measure in differentiating within normal limits, MCI, and AD when
looking at the memory/word list section in particular. Additionally, the SVLT
appears to be a strong measure to aid in diagnosing within normal limits, MCI, and
AD. Regarding the MoCA, it would be important to further explore its utility as an
independent tool to assistant with differential diagnosis of dementias and
neurodegenerative diseases. Additionally, more research regarding the SVLT
would be beneficial to determine specific cut scores regarding MCI and AD
diagnosis, as it appears to be an adequate tool for measuring verbal memory in
these populations. Furthermore, overall, more research with the SVLT would be
beneficial to see the utility it provides regarding its diagnostic capabilities with the
broader spectrum of neurodegenerative diseases.
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